SA
CRDF

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.4 · elevated volatility

Overview →

Cardiff Oncology is a clinical-stage biotechnology company focused on developing PLK1 inhibitor onvansertib for RAS-mutated cancers. The company has no commercial revenue and operates as a pure R&D entity, with its primary asset being onvansertib in Phase 1b/2 trials for KRAS-mutated metastatic colorectal cancer and metastatic castration-resistant prostate cancer. Stock value is entirely driven by clinical trial readouts, regulatory milestones, and partnership potential.

HealthcareClinical-Stage Oncology Biotechnologylow - Clinical-stage biotechs have high fixed costs (clinical trial expenses, personnel, regulatory compliance) with no revenue to offset them. Operating leverage only materializes post-commercialization when manufacturing and sales infrastructure can scale. Current burn rate of approximately $25-30M annually with minimal variable cost structure.

Business Overview

01No current revenue - pre-commercial stage
02Potential future milestone payments from strategic partnerships (not yet established)
03Potential future royalties on commercialized products (5-10+ years out)

Cardiff operates as a clinical-stage biotech with no current revenue generation. The business model relies on advancing onvansertib through clinical trials to demonstrate efficacy in RAS-mutated cancers, then either partnering with larger pharma companies for commercialization (receiving upfront payments, milestones, and royalties) or pursuing independent commercialization if sufficient capital is raised. The company's value proposition centers on targeting PLK1, a cell cycle regulator overexpressed in RAS-mutated tumors, which represent approximately 30% of all cancers. Pricing power will depend entirely on clinical differentiation versus existing standards of care and competitive checkpoint inhibitors.

What Moves the Stock

Clinical trial data readouts for onvansertib in KRAS-mutated mCRC and mCRPC trials - positive efficacy/safety data can drive 50-100%+ moves

Partnership announcements with major pharmaceutical companies for co-development or commercialization rights

FDA regulatory milestone achievements (IND approvals, Fast Track designation, Breakthrough Therapy designation)

Equity financing announcements and cash runway updates - dilution concerns or extended runway clarity

Competitive developments in PLK1 inhibitor space or alternative RAS-targeting therapies

Watch on Earnings
Clinical trial enrollment rates and timeline updates for ongoing Phase 1b/2 studiesCash burn rate and runway extension (quarters of liquidity remaining)Patient response rates, progression-free survival, and overall survival data from ongoing trialsStrategic partnership discussions and business development pipeline updates

Risk Factors

Clinical trial failure risk - onvansertib may not demonstrate sufficient efficacy or acceptable safety profile in ongoing trials, rendering the asset worthless

Competitive obsolescence - rapid advancement in RAS-targeting therapies (KRAS G12C inhibitors like sotorasib, adagrasib) and combination immunotherapies may make PLK1 inhibition less differentiated

Regulatory pathway uncertainty - FDA approval requirements for RAS-mutated cancers continue evolving, potentially requiring larger/longer trials than anticipated

Capital markets access risk - biotech funding cycles are highly volatile; inability to raise capital at reasonable valuations could force asset sales or wind-down

Direct PLK1 inhibitor competition from larger pharma with deeper resources and faster development timelines

Indirect competition from combination therapies pairing checkpoint inhibitors with targeted agents showing superior efficacy in RAS-mutated populations

Partnership risk - inability to secure pharma partner may require independent commercialization beyond company's financial capacity

Cash runway depletion - with $25-30M annual burn and approximately $30-35M in cash (estimated from current ratio and market cap), company likely needs financing within 12-18 months

Equity dilution risk - future financing rounds at depressed valuations (stock down 63% YoY) will significantly dilute existing shareholders

Going concern risk - if clinical data disappoints and capital markets remain closed, company may lack resources to complete trials

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital and may delay patient enrollment if healthcare access is constrained. Biotech sector sentiment is more correlated with risk appetite than economic fundamentals.

Interest Rates

Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-12+ years out for potential commercialization). Clinical-stage biotechs with no earnings are particularly sensitive to rate changes as their entire value is based on discounted terminal values. Higher rates also increase cost of capital for future financing rounds and make risk-free alternatives more attractive to investors, reducing speculative capital flows into biotech.

Credit

minimal - Company maintains strong balance sheet with 4.20x current ratio and minimal debt (0.02 D/E ratio). Credit conditions primarily affect ability to raise equity capital rather than debt financing. Tightening credit can reduce institutional appetite for speculative biotech investments.

Live Conditions
Russell 2000 FuturesS&P 500 FuturesDow Jones Futures

Profile

growth - Attracts highly speculative, risk-tolerant investors seeking asymmetric returns from binary clinical trial outcomes. Typical shareholders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance. Not suitable for value or income investors given lack of earnings, dividends, or tangible book value. Momentum traders enter around data catalyst events.

high - Clinical-stage biotechs exhibit extreme volatility with 50-100%+ single-day moves around trial data releases. Stock has declined 63% over past year, demonstrating downside volatility. Beta likely exceeds 2.0 relative to broader market. Options implied volatility typically elevated (60-100%+) ahead of data readouts.

Key Metrics to Watch
Onvansertib Phase 1b/2 trial interim data releases - objective response rates and progression-free survival versus historical controls
Cash and cash equivalents quarterly burn rate - runway to next financing event
NASDAQ Biotechnology Index (NBI) performance - sector sentiment proxy for funding environment
Federal Funds Rate and 10-Year Treasury yield - discount rate impact on long-duration biotech valuations
Competitor clinical trial results in RAS-mutated cancer space - validates or undermines target biology
Biotech IPO and follow-on offering activity - signals capital markets accessibility
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.